Trial Information
PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations
Inclusion Criteria:
- Patients with newly diagnosed or relapsed AML
- AML FAB M0-2, M4-7
- Signed informed consent after patient information
- Male and female patients with AML age 18-80
- 18FDG-PET-CT is available within a period of 5 days after diagnosis of AML
Exclusion Criteria:
- AML FAB M3 (Promyelocytic Leukemia)
- lacking willingness to cooperate
- pregnancy or insufficient contraception
- 18FDG-PET-CT is not available within a period of 5 days after diagnosis of AML
- Medical condition of the patients requires an immediated start of chemotherapy
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Authority:
Germany: Federal Office for Radiation Protection
Study ID:
TUD-PETAML-043
NCT ID:
NCT01278069
Start Date:
February 2011
Completion Date:
May 2015
Related Keywords:
- Newly Diagnosed or Relapsed Acute Myeloid Leukemia
- Acute myeloid Leukemia
- Myeloid Sarcoma
- Extramedullary Acute myeloid Leukemia
- 18FDG-PET-CT
- Leukemia
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid